Venetoclax for an ATRA and ATO resistance acute promyelocytic leukemia patient with TNRC18::RARA fusion gene

IF 0.7 Q4 HEMATOLOGY Leukemia Research Reports Pub Date : 2024-01-01 DOI:10.1016/j.lrr.2024.100482
Weina Li , Haijie Li , Xueyan Chen , Yan Zheng
{"title":"Venetoclax for an ATRA and ATO resistance acute promyelocytic leukemia patient with TNRC18::RARA fusion gene","authors":"Weina Li ,&nbsp;Haijie Li ,&nbsp;Xueyan Chen ,&nbsp;Yan Zheng","doi":"10.1016/j.lrr.2024.100482","DOIUrl":null,"url":null,"abstract":"<div><div>Variant acute promyelocytic leukemia (APL) poses diagnostic and therapeutic challenges primarily because of the absence of <em>PML::RARA.</em> This report presents the case of a patient diagnosed with <em>all-trans</em> retinoic acid (ATRA)-resistant APL harboring the <em>TNRC18::RARA</em> fusion gene. After treatment with venetoclax, azacitidine, and ATRA, the patient achieved complete remission. The patient also developed pulmonary tuberculosis and a multidrug-resistant infection, which improved considerably after antituberculosis treatment and carrimycin, respectively.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100482"},"PeriodicalIF":0.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048924000724","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Variant acute promyelocytic leukemia (APL) poses diagnostic and therapeutic challenges primarily because of the absence of PML::RARA. This report presents the case of a patient diagnosed with all-trans retinoic acid (ATRA)-resistant APL harboring the TNRC18::RARA fusion gene. After treatment with venetoclax, azacitidine, and ATRA, the patient achieved complete remission. The patient also developed pulmonary tuberculosis and a multidrug-resistant infection, which improved considerably after antituberculosis treatment and carrimycin, respectively.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Venetoclax 治疗 TNRC18::RARA 融合基因的 ATRA 和 ATO 抗性急性早幼粒细胞白血病患者
变异型急性早幼粒细胞白血病(APL)给诊断和治疗带来了挑战,主要原因是缺乏 PML::RARA。本报告介绍了一例被诊断为携带 TNRC18::RARA 融合基因的全反式维甲酸(ATRA)耐药 APL 患者的病例。在接受venetoclax、阿扎胞苷和ATRA治疗后,患者获得了完全缓解。该患者还患上了肺结核和耐多药感染,在分别接受抗结核治疗和卡林霉素治疗后,病情有了很大改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Leukemia Research Reports
Leukemia Research Reports Medicine-Oncology
CiteScore
1.70
自引率
0.00%
发文量
70
审稿时长
23 weeks
期刊最新文献
Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies: A case report Acute lower limb ischemia revealing hypo granular acute promyelocytic leukemia Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country Late-onset Familial Hemophagocytic Lymphohistiocytosis in a survivor of Hodgkin's Lymphoma Posterior reversible encephalopathy syndrome (PRES) and myeloma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1